Tango Therapeutics Launches $400M At-the-Market Equity Program, Replacing Prior $100M ATM
TNGX has more than doubled off its 52-week low of $6.25.
Summary
Tango Therapeutics filed a prospectus supplement for a new $400 million at-the-market equity offering program, replacing its prior $100 million ATM. The company can now sell shares gradually to fund its oncology pipeline, adding potential dilution but extending its financial runway.
Key Events · Financing and Capital Events · TNGX
-
New $400M ATM Program Launched
Tango Therapeutics established a new at-the-market equity offering program for up to $400 million of common stock, replacing its prior $100 million ATM program under which approximately $64.4 million had been sold.
-
Potential Dilution
At the assumed offering price of $27.07 per share, the new program could result in the issuance of up to approximately 14.8 million shares, representing about 8.8% of the current outstanding shares.
-
Use of Proceeds
Net proceeds will be used for general corporate purposes, including funding research and development of product candidates such as vopimetostat and TNG456, manufacturing, and clinical trial expenses.
-
Sales Agent and Terms
Leerink Partners will act as sales agent, receiving a commission of up to 3.0% of gross sales. Sales will be made at market prices from time to time.
Analysis · TNGX · Life Sciences
Tango Therapeutics is replacing its existing $100 million at-the-market (ATM) program with a new $400 million ATM facility. The prior program had sold about $64.4 million of stock. The new program, managed by Leerink Partners, allows the company to sell shares into the market over time at prevailing prices. While this provides significant financial flexibility to fund its oncology pipeline—including the promising vopimetostat/daraxonrasib combination—it also creates a potential overhang of up to roughly 15 million shares (based on recent prices), which could pressure the stock. The move follows a $600 million public offering in June 2026 and comes as the company holds $1.0 billion in cash, suggesting a proactive approach to capital raising rather than a near-term cash need.
At the time of this filing, TNGX was trading at $26.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $6.25 to $34.39. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.